RT Journal Article
SR Electronic
T1 Whole genome analysis in <em>APOE4</em> homozygotes identifies the <em>DAB1-RELN</em> pathway in Alzheimer’s disease pathogenesis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.28.22274418
DO 10.1101/2022.04.28.22274418
A1 Bracher-Smith, Matthew
A1 Leonenko, Ganna
A1 Baker, Emily
A1 Crawford, Karen
A1 Graham, Andrew C.
A1 Salih, Dervis A.
A1 Howell, Brian W.
A1 Hardy, John
A1 Escott-Price, Valentina
YR 2022
UL http://medrxiv.org/content/early/2022/04/28/2022.04.28.22274418.abstract
AB The APOE-ε4 allele is known to predispose to amyloid deposition and consequently is strongly associated with Alzheimer’s disease (AD) risk. There is debate as to whether the APOE gene accounts for all genetic variation of the APOE locus. Another question which remains is whether APOE-ε4 carriers have other genetic factors influencing the progression of amyloid positive individuals to AD. We conducted a genome-wide association study in a sample of 5,390 APOE-ε4 homozygous (ε4ε4) individuals (288 cases and 5,102 controls) aged 65 or over in the UK Biobank. We found no significant associations of SNPs in the APOE locus with AD in the sample of ε4ε4 individuals. However, we identified a novel genome-wide significant locus associated to AD, mapping to DAB1 (rs112437613, OR=2.28, CI=1.73-3.01, p=5.4×10−9). This identification of DAB1 led us to investigate other components of the DAB1-RELN pathway for association. Analysis of the DAB1-RELN pathway indicated that the pathway itself was associated with AD, therefore suggesting an epistatic interaction between the APOE locus and the DAB1-RELN pathway.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was largely funded by the UK DRI, which receives its funding from the DRI Ltd, funded by the UK Medical Research Council (UKDRI-3003), Alzheimer's Society and ARUK. JH is supported by the Dolby Foundation, and by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. D.A.S. also received funding from the Alzheimer's Research UK (ARUK) pump priming scheme via the UCL network. VEP is supported by Joint Programming for Neurodegeneration (JPND) - (MRC: MR/T04604X/1).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of the North-West Multi-Centre Research Ethics Committee gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData for this study was obtained under UK Biobank application 15175. Data is available from the UK Biobank at www.ukbiobank.ac.uk.